Helsinn Group Hosts a Satellite Symposium on Shared Decision Making in Supportive Care, at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual Meeting 2016 on June 24th

News provided by

Helsinn Group

13 Jun, 2016, 07:00 GMT

LUGANO, Switzerland, June 13, 2016 /PRNewswire/ --

A Panel of World-renowned Experts Will Share Practical Recommendations on Best Practice in Supporting People With Cancer, Offering Advice on Multidisciplinary Approaches and Finding Practical Solutions  

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it is supporting a Satellite Symposium:

Shared decision making in cancer supportive care: a symptom-free journey for patients; at the MASCC/ISOO Annual Meeting 2016 to be held in Adelaide Convention Center, Hall M from 12.30 to 2pm. The symposium brings together experts in cancer supportive care to discuss multidisciplinary approaches and to find practical solutions to a range of problems affecting people with cancer. The discussion will include case-based scenarios in areas including toxicity in cancer treatment, and management of nutrition impact symptoms including anorexia, nausea and stomatitis.

The symposium will be chaired by Professor Dorothy Keefe, Professor of Cancer Medicine at the University of Adelaide, Australia. Panel members will include Jervoise Andreyev, Consultant Gastroenterologist in Pelvic Radiation Disease at the Royal Marsden Hospital in London, UK, Snezana Bosnjak, Consultant Clinical Pharmacologist at the Institute for Oncology and Radiology of Serbia, and David Currow, Professor of Palliative and Supportive Services at Flinders University, Adelaide, Australia.

The symposium will be held on Friday, June 24th, from 12.30 noon until 14.00pm at the Adelaide Convention Center, Hall M.

Professor Dorothy Keefe commented: "Shared decision making is a vital and often overlooked element of providing the most appropriate care to people with cancer. The more we share our knowledge the more we can improve the standard of care for all people with cancer."

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, commented: "Helsinn is committed to helping people with cancer get the best out of every day and so, in conjunction with our five-year long sponsorship of the congress, this year we are also delighted to support this satellite symposium at the MASCC/ISOO annual meeting. We look forward to hearing from a world class panel of speakers as they share their expertise in helping manage the side effects of cancer and help us improve our collective knowledge of this area, and ultimately, improve the lives of patients worldwide."  

In addition to this symposium, Helsinn submitted seven abstracts to the MASCC Annual Meeting on a range of topics relating to supportive care in cancer treatment, including management of CINV and cancer anorexia-cachexia..

About the Helsinn Group 

Helsinn is a privately owned cancer supportive care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.

In 2016, our 40th anniversary year, you can meet representatives from Helsinn at:

  • MASCC Annual Meeting (Adelaide, Australia, 23-25 June)
  • ChemOutsourcing Conference (Parsippany, New Jersey, 19-21 September)
  • CPhI Worldwide (Barcelona, Spain, 4-6 October)
  • ESMO Congress (Copenhagen, Denmark, 7-11 October)
  • BioEurope (Köln, Germany, 4-6 November)

As part of its patient-centered mission and support of the oncology community, Helsinn works closely with Patient Advocacy Groups. These key stakeholders protect the interests of cancer patients by helping them to receive appropriate and timely care, education, support and financial assistance, when needed.

For more information, please visit http://www.helsinn.com

For more information, please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
Tel: +41 91-985-21-21
info-hhc@helsinn.com